drugset / Trial / NCT00106600
Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The goal of this study is to find the safest dose of Pixantrone (BBR 2778) that can be given to patients with Acute Myelogenous Leukemia (AML). After the safest dose is found, up to an additional 86 patients will be enrolled. During this part of the study, the safety and effectiveness will be evaluated.
Timeline
- Start
- 2005-03
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pixantrone | Small molecule | — | Intravenous |